Genmab, GlaxoSmithKline deal

Genmab received its second and third milestone payments, of DKK87.2 million ($16.9 million) each, from GlaxoSmithKline under a 2006 deal to co-develop and commercialize Genmab's ofatumumab ( HuMax-CD2...